Introduction and Objectives: Patients taking amino-bisphosphonatesmay develop jawbone disease. We evaluated theclinical, radiological and histological features of bisphosphonateassociatedjawbone disease with the aim of defining the natureof bone lesions and the possible pathogenesis.Methods: Thirty-five consecutive patients with bisphosphonateassociatedjawbone disease were studied. Clinical and radiologicalassessment were performed; the number and featuresof each lesion and history of previous traumatic events wererecorded. Eleven patients underwent extensive jawbone resection.Resected jaws were subjected to histological analysis. Basedon CT and MRI findings, bone specimens were obtained fromexposed necrotic areas, unexposed areas and resec...
Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well know...
Purpose Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases...
Background: Intravenous bisphosphonates are the current standard of care for the treatment of hyperc...
Introduction and Objectives: Patients taking amino-bisphosphonatesmay develop jawbone disease. We ev...
Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisph...
Introduction: Patients undergoing bisphosphonate therapies may develop jaw lesions, mainly consistin...
Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisph...
ObjectiveTo assess the main clinical, radiographic, and histopathologic features of patients with bi...
Background. Bisphosphonates are drugs used in the treatment of lytic bone metastases, multiple myelo...
Bone necrosis of the jaws is often related to head and neck radiotherapy, to surgical procedures at ...
Bisphosphonates have been prescribed for the treatments of oncologic and metabolic bone diseases to ...
The maxillary and mandibular bones undergo high-turnover remodeling to maintain mechanical competenc...
Jaw bone necrosis is a clinical condition associated with defects in vascularization of the maxilla ...
The maxillary and mandibular bones undergo high-turnover remodeling to maintain mechanical competenc...
Objective. To describe the histological features of bone tissue harvested from patients affected by ...
Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well know...
Purpose Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases...
Background: Intravenous bisphosphonates are the current standard of care for the treatment of hyperc...
Introduction and Objectives: Patients taking amino-bisphosphonatesmay develop jawbone disease. We ev...
Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisph...
Introduction: Patients undergoing bisphosphonate therapies may develop jaw lesions, mainly consistin...
Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisph...
ObjectiveTo assess the main clinical, radiographic, and histopathologic features of patients with bi...
Background. Bisphosphonates are drugs used in the treatment of lytic bone metastases, multiple myelo...
Bone necrosis of the jaws is often related to head and neck radiotherapy, to surgical procedures at ...
Bisphosphonates have been prescribed for the treatments of oncologic and metabolic bone diseases to ...
The maxillary and mandibular bones undergo high-turnover remodeling to maintain mechanical competenc...
Jaw bone necrosis is a clinical condition associated with defects in vascularization of the maxilla ...
The maxillary and mandibular bones undergo high-turnover remodeling to maintain mechanical competenc...
Objective. To describe the histological features of bone tissue harvested from patients affected by ...
Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well know...
Purpose Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases...
Background: Intravenous bisphosphonates are the current standard of care for the treatment of hyperc...